Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SH-1028 + rifampicin
- Development stage
- Unknown
- Lead developer
- Nanjing Sanhome Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**SH-1028 + rifampicin** is a combination used to study drug-drug interactions between SH-1028 and rifampicin. SH-1028 is an *irreversible third-generation EGFR tyrosine kinase inhibitor* developed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), particularly in patients with the EGFR T790M mutation[1][2][5]. Rifampicin is used as a *strong inducer* of cytochrome P450 CYP3A4 to assess its impact on the pharmacokinetics and metabolism of SH-1028[1]. The combination is not an approved therapy, but rather a regimen used in clinical pharmacology studies to investigate the metabolic profile, safety, and pharmacokinetic interactions of SH-1028 when administered alongside a CYP3A4 inducer.
- Other names
- SH-1028SH1028SH 1028oritinibrilertinibrifampicin
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on SH-1028 + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH-1028 + rifampicin.